XML 76 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Note A - Organization and Summary of Significant Accounting Policies (Details Textual)
$ / shares in Units, € in Millions
3 Months Ended 12 Months Ended
Sep. 30, 2017
USD ($)
Aug. 07, 2017
shares
Sep. 30, 2019
USD ($)
Dec. 28, 2018
USD ($)
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
$ / shares
shares
Jul. 01, 2019
USD ($)
Jun. 30, 2019
EUR (€)
shares
Foreign Currency Contract, Asset, Fair Value Disclosure         $ 2,300,000 $ 55,000    
Foreign Currency Contracts, Liability, Fair Value Disclosure           55,000    
Financing Receivable, after Allowance for Credit Loss, Current, Total         1,500,000    
Investment Income, Interest         1,868,000 1,085,000    
Inventory Valuation Reserves, Ending Balance         1,106,000 372,000    
Impairment of Long-Lived Assets to be Disposed of         0 0    
Sales Discounts, Noncash         82,000 898,000    
Sales, Royalty and Licensing Revenue         16,700,000 21,400,000    
Royalty Expense         686,000 854,000    
Research and Development Expense, Total         1,800,000 1,500,000    
Advertising Expense         $ 1,600,000 $ 2,400,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares         0 0    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares         5,000 0    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value         $ 0 $ 0    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Beta Alanine Raw Material Sale Customers [Member]                
Concentration Risk, Percentage         8.00% 17.30%    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]                
Concentration Risk, Percentage         76.80% 76.60%    
Restricted Stock 1 [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares         0 41,661    
The 2009 Omnibus Stock Incentive Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares         1,400,000     1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares         229,000     229,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares         5,000      
Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares         190,000 175,000    
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount         $ 3,500,000      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition         2 years 109 days      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares         $ 11.57 $ 11.30    
Restricted Stock [Member] | The 2009 Omnibus Stock Incentive Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares         190,000      
Restricted Stock [Member] | Juice Plus, Amended and Restated Exclusive Manufacturing Agreement [Member]                
Treasury Stock, Shares, Acquired | shares         400,000      
Share-based Payment Arrangement, Option [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate         0.00%      
Foreign Exchange Contract [Member]                
Derivative, Notional Amount         $ 39,900,000     € 32.5
Minimum [Member]                
Property, Plant and Equipment, Useful Life         1 year      
Minimum [Member] | Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         3 years      
Maximum [Member]                
Property, Plant and Equipment, Useful Life         39 years      
Maximum [Member] | Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         5 years      
SR CarnoSyn Powder [Member]                
Inventory Valuation Reserves, Ending Balance         $ 686,000      
Kaged Muscle LLC [Member] | Notes Receivable [Member]                
Notes, Loans and Financing Receivable, Term 1 year              
Financing Receivable, after Allowance for Credit Loss, Current, Total $ 1,500,000              
Notes, Loans and Financing Receivable, Extension Fee       $ 25,000        
Notes, Loans and Financing Receivable, Interest Rate, Stated Percentage 15.00%              
Investment Income, Interest         104,000 $ 171,000    
Juice Plus + [Member]                
Agreement, Term   5 years            
Juice Plus + [Member] | Restricted Stock [Member]                
Stock Issuance Agreement, Shares Agreed to Grant | shares   500,000            
Sales Discounts, Noncash         82,000 898,000    
Sales Discounts, Cash         395,000 0    
Fair Value, Inputs, Level 3 [Member]                
Fair Value, Net Asset (Liability), Total         0 0    
Fair Value, Inputs, Level 1 [Member]                
Fair Value, Net Asset (Liability), Total         0 0    
Reclassification out of Accumulated Other Comprehensive Income [Member] | Forecast [Member]                
Cumulative Effect on Retained Earnings, Net of Tax, Total     $ 134,000          
Nonoperating Income (Expense) [Member]                
Gain (Loss) on Derivative Instruments, Net, Pretax, Total         $ 1,600,000 $ 900,000    
Accounting Standards Update 2016-02 [Member] | Subsequent Event [Member]                
Operating Lease, Liability, Total             $ 20,400,000  
Operating Lease, Right-of-Use Asset             $ 20,300,000